Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | RAD52 | P43351 | 3/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 2/20 | 0.42 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7262455 | 0.86 | KDM4E (0.43) | KDM4EALDH1A1POLBRAD52GLA | |
| SCHEMBL11341944 | 0.84 | ELANE (0.42) | KDM4EALDH1A1POLBRAD52GLA | |
| SCHEMBL2532916 | 0.84 | TNKS2 (0.46) | KDM4EALDH1A1POLBRAD52GLA | |
| SCHEMBL3964725 | 0.84 | KDM4E (0.40) | KDM4EALDH1A1POLBGLALMNA | |
| SCHEMBL7262454 | 0.81 | KDM4E (0.40) | KDM4EALDH1A1POLBGLAGAA | |
| SCHEMBL4278249 | 0.81 | KDM4E (0.49) | KDM4EALDH1A1POLBRAD52GLA | |
| SCHEMBL472912 | 0.80 | MEN1 (0.42) | KDM4EALDH1A1POLBRAB9ALMNA | |
| SCHEMBL64767 | 0.78 | MYC (0.52) | KDM4EALDH1A1POLBRAD52GLA | |
| SCHEMBL29376440 | 0.78 | MYC (0.52) | KDM4EALDH1A1POLBRAD52GLA | |
| SCHEMBL3972718 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1POLBRAD52GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | claimed |
| EP-2997382-B1 | ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF | UNIV NOTTINGHAM (GB) | 2018-07-11 | — | — | EP | disclosed |
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1590328-A4 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARM INC (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
| EP-1807419-A1 | (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS | OSI Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006047574-A1 | (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| US-6984648-B2 | Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| US-6962938-B2 | Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-6495548-B1 | SUCH AS 3-((2,2-DIMETHYL-1-OXOPROPYL)AMINO)-N-HYDROXY-1-(4-((2-METHYL-4 -QUINOLINYL)METHOXY)PHENYL)-2-OXO-3-PYRROLIDINE ACETAMIDE; PREVENTING UNCONTROLLED BREAKDOWN OF CONNECTIVE TISSUE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1263755-A2 | CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2002074738-A2 | SPIRO-CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF-ALPHA CONVERTING ENZYME (TAGE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-26 | — | — | WO | disclosed |
| US-6455522-B1 | ANTIINFLAMMATORY AGENTS; AGGRECANASE AND TUMOR NECROSIS FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
| WO-2002004416-A2 | LACTAM METALLOPROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001070673-A2 | CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-1027332-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-08-16 | — | — | EP | disclosed |
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |
| WO-1999018074-A1 | NOVEL LACTAM METALLOPROTEASE INHIBITORS | Britol-Myers Squibb Pharma Company (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | KDM4E 2397/4885ALDH1A1 839/4885POLB 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.